Aeluma is a risky investment because its roughly $300M market cap rests on about $5M of revenue from government R&D, with zero commercial customers. Its III-V-on-silicon technology is real, but the open question is who buys outside government. The near-50% surge on $4M of US government contracts, with Tower Semiconductor and Sumitomo Chemical handling wafers, looks like an overreaction to a contract that is not large; the stock trades at about 58x sales alongside a $50M ATM and insider selling. … Show more

Aeluma looks more like a university project than a company, so its price has been badly speculative without reason. If its technology proves useful, it will likely be acquired, but it does not merit more time or effort. x.com  x.com 

Aeluma is a speculative small cap with a rare ability to put compound semiconductors on standard 200mm and 300mm silicon, making quantum dot lasers, nonlinear photonics and detectors that feed CPO, VCSELs and quantum photonic ICs. A seed investor is Shuji Nakamura, the Nobel laureate who co-invented the blue LED. Catalysts include $4M+ in government contracts, Tower Semi and Sumitomo partnerships, and DARPA, NASA and Navy customers. Risks are a $50M ATM, heavy insider selling and no revenue yet. … Show more

Aeluma's stock already prices in much of a successful FY28-FY29 commercialization, while commercial revenue is minimal and no volume customers are publicly named. Its III-V-on-silicon technology is real, but of $2.657M in revenue for the six months to December 2025, only $41k came from non-government work, and Q2 revenue fell year over year. Most of its 20+ customer engagements are still in evaluation or prototyping, and government contracts de-risk the physics, not adoption. x.com 

Lumentum and Coherent are investments driven by product iteration, while AXT is a bottleneck trade best treated as speculation. Shortage-driven price hikes on the same parts define a cyclical stock, prices quickly discount shortage expectations, and once profits truly climb it is time to exit. Bottlenecks also push customers to design around them and invite new entrants. Investable companies keep lifting margins through yield gains and new products, driving token deflation while growing revenue. … Show more

Aeluma is in almost the same setup as Lightwave Logic before its big run, after winning over $4M in US government contracts for quantum dot lasers and quantum nonlinear materials with Tower Semiconductor as manufacturing partner. Lightwave Logic, small and pre-revenue with Tower and government validation, rose 138% in a month. Aeluma's lasers target AI data center links as speeds push toward 3.2T. It is even earlier stage, so upside is larger if the technology converts, but risk is high. x.com 

Applied Optoelectronics' roughly $12B valuation is absurd any way you look at it, even after management raised its mid-2027 projection to $471M in monthly revenue. It doesn't hold up on 2027 revenue, let alone earnings or the margin compression co-packaged optics would bring. Management will keep overpromising and underdelivering, could face legal trouble over what looks like a pump and dump, and has been in such trouble before; its own employees deride the company. x.com  x.com  x.com 

Credo's case rests on expanding its share of the AI connectivity stack, not on AEC keeping its extraordinary growth. AEC remains its largest business, with healthy growth and deep ties to five hyperscalers. Optical expands rather than merely replaces it: optical DSP, silicon photonics PICs and ZeroFlap optics should bring over $600M of revenue in FY2027, so a smaller AEC share is fine if the company grows. After its microLED ALC reveal, Credo looks clearly undervalued. x.com  x.com  x.com  x.com  … Show more

Aeluma's post-earnings drop looks like a reaction to headline numbers, while the call's tone suggests more customers are qualifying its technology. That makes the $26-27 area attractive for long-run believers, with support at the 10-day EMA and prior $25.94 high and a path to $35.65 if it holds. It remains an extremely high-risk bet: a market cap in the hundreds of millions against minuscule revenue, resting on a customer win. @NickNemo17's critical research makes valid points. x.com  x.com  x.com 

Aeluma's technology is ready but meaningful revenue is still far off, so it is a wait-and-see stock until a signed purchase order arrives. Q3 revenue of $1.2M missed the $1.35M consensus and FY2026 guidance narrowed to $4.2-4.6M, blamed on government contract delays. It grows quantum-dot lasers on 200mm silicon with MOCVD and has moved production to Tower Semiconductor, but H2 2026 is for sampling and yields; problems in the first qualification could add long delays. x.com  x.com